Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | FDPS | P14324 | 3/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19302676 | 1.00 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1FDPSSPHK1 | |
| SCHEMBL19226278 | 1.00 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1FDPSSPHK1 | |
| SCHEMBL23771912 | 1.00 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1FDPSSPHK1 | |
| SCHEMBL20031996 | 0.96 | CYP19A1 (0.35) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL28275409 | 0.91 | CYP19A1 (0.34) | CYP19A1OPRM1TBXAS1 | |
| Bromide SCHEMBL29191437 | 0.86 | OPRM1 (0.36) | CYP19A1OPRM1TBXAS1SPHK1 | |
| SCHEMBL11194903 | 0.81 | OPRM1 (0.39) | CYP19A1OPRM1TBXAS1SPHK1 | |
| SCHEMBL20397465 | 0.80 | CYP19A1 (0.34) | CYP19A1OPRM1TBXAS1 | |
| SCHEMBL27995273 | 0.80 | ADA (0.35) | OPRM1 | |
| SCHEMBL27995100 | 0.80 | ADA (0.35) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-02-11 | — | — | US | disclosed |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | PHARMAKEA, INC. | 2019-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371380-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | CYP19A1 2118/4885OPRM1 54/4885TBXAS1 179/4885 |
| US-20190233411-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP19A1 3392/4885OPRM1 4085/4885TBXAS1 3413/4885 |
| US-20210040083-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | CYP19A1 3392/4885OPRM1 4085/4885TBXAS1 3413/4885 |
| US-20190046520-A1 | QUINOLINONE LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF | LOXL2, LOXL1, LOX | CYP19A1 1197/4885OPRM1 2098/4885TBXAS1 295/4885 |
| US-10588900-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | CYP19A1 1197/4885OPRM1 2098/4885TBXAS1 295/4885 |
| US-10793563-B2 | GCN2 inhibitors and uses thereof | EIF2AK4, GCN1, GCGR | CYP19A1 3392/4885OPRM1 4085/4885TBXAS1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.